- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.01. | PSYENCE BIOMEDICAL LTD. - F-1, Registration statement for certain foreign private issuers | - | SEC Filings | ||
| 23.01. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| PSYENCE BIOMEDICAL Aktie jetzt für 0€ handeln | |||||
| 31.12.24 | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 27.12.24 | Psyence Biomedical Ltd.: Psyence Biomed Announces Closing of $2.0 Million Private Placement | 2 | GlobeNewswire (USA) | ||
| 23.12.24 | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 23.12.24 | Psyence Biomed announces $2 million private placement | 2 | Investing.com | ||
| 23.12.24 | Psyence Biomedical dips 18%, prices $2M offering | 1 | Seeking Alpha | ||
| 23.12.24 | Psyence Biomedical Ltd.: Psyence Biomed Announces $2.0 Million Private Placement | 1 | GlobeNewswire (USA) | ||
| 23.12.24 | Psyence Biomedical regains compliance with Nasdaq | 1 | Seeking Alpha | ||
| 23.12.24 | Psyence Biomedical Ltd.: Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements | 149 | GlobeNewswire (Europe) | NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence Biomed" or the "Company") today announced that it has received notice from the Nasdaq Hearings panel that... ► Artikel lesen | |
| 20.12.24 | PSYENCE BIOMEDICAL LTD. - F-1, Registration statement for certain foreign private issuers | - | SEC Filings | ||
| 20.12.24 | Pre-market Movers: My Size, Nvni Group, Psyence Biomedical, Humacyte, PainReform | 590 | AFX News | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.55 A.M. ET).In the Green My Size, Inc. (MYSZ) is up over 372% at $6.43.
Nvni... ► Artikel lesen | |
| 18.12.24 | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 17.12.24 | Optimi Health Corp: Optimi Health signs agreement with Psyence Biomedical | 3 | Stockwatch | ||
| 17.12.24 | Psyence Biomedical Ltd.: Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial | 219 | GlobeNewswire (Europe) | Patient screening underway; first patient expected to be randomized into the study in January A leading clinical trial site management organization (SMO), Australian Clinical Trial Network (ACTioN)... ► Artikel lesen | |
| 17.12.24 | Optimi Health Corp.: Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed's Phase IIb Palliative Care Trial | 275 | Newsfile | Agreement Supports Phase IIb and Future Phase III Trial Development,Addressing Critical Needs in Palliative Care Using Optimi's Natural Psilocybin ExtractVancouver, British Columbia--(Newsfile Corp.... ► Artikel lesen | |
| 10.12.24 | Psyence Biomedical stock soars on binding agreements with Optimi Health | 4 | Seeking Alpha | ||
| 10.12.24 | Psyence Biomedical Ltd.: Psyence Biomed Executes Binding Agreements with Optimi Health Corp. | 84 | GlobeNewswire (Europe) | NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence Biomed" or the "Company") today announced that it has progressed beyond the previously-announced non-binding... ► Artikel lesen | |
| 06.12.24 | Psyence Group Inc: Psyence to receive Psyence Biomedical shares for debt | 2 | Stockwatch | ||
| 06.12.24 | Psyence Group Inc.: Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations | 1 | GlobeNewswire (USA) |
Seite:
1 2 3 4 Weiter >>
79 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOLINERX | 3,283 | -100,00 % | XFRA YP2: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILBIOLINERX LTD. DL-... ► Artikel lesen | |
| TRANSCODE THERAPEUTICS | 8,200 | -12,49 % | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial | No significant safety or dose limiting toxicities reported
PK data from Cohorts 1 and 2 consistent with preclinical and Phase 0 trial results
BOSTON, Feb.... ► Artikel lesen | |
| SILEXION THERAPEUTICS | 0,840 | -5,62 % | Pre-market Movers: China Liberal Education, CARGO Therapeutics, Tectonic Therapeutic, Silexion Therapeutics, Banzai International | SANDY SPRINGS (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.35 A.M. ET).In the Green Tectonic Therapeutic, Inc. (TECX) is up over... ► Artikel lesen | |
| MINK THERAPEUTICS | 0,830 | 0,00 % | MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements | NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic... ► Artikel lesen | |
| QIAGEN | 37,375 | -0,33 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 54,90 auf 48,00 Euro gesenkt und die Einstufung auf "Buy" belassen. Das vierte Quartal sei solide gewesen, auch... ► Artikel lesen | |
| TEMPUS AI | 68,13 | -11,20 % | Tempus AI Aktie: Langfristige Planung vorgestellt | Der Technologiekonzern Tempus AI verzeichnet derzeit bemerkenswerte Bewegungen im Aktienhandel, wobei mehrere hochrangige Führungskräfte in der vergangenen Woche umfangreiche Aktienverkäufe tätigten.... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 34,560 | -0,95 % | Harmony Biosciences price target cut to $42 at Mizuho | ||
| ARVINAS | 17,770 | -3,27 % | Arvinas Inc.: Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | - Announced that topline data from the monotherapy Phase 3 VERITAC-2 trial is anticipated in 1Q25 - - Presented Phase 1b data from the TACTIVE-U sub-study of vepdegestrant in combination with... ► Artikel lesen | |
| DYNE THERAPEUTICS | 14,010 | 0,00 % | Dyne Therapeutics SVP Richard Scalzo verkauft Aktien im Wert von 34.707 US-Dollar | ||
| RECURSION PHARMACEUTICALS | 9,265 | -10,48 % | Cathie Wood Explains Why She Likes Recursion Pharmaceuticals, Inc. (RXRX) | ||
| SPRINGWORKS THERAPEUTICS | 58,24 | -2,77 % | Merck KGaA: Wechsel im Top-Management - wann schlägt der DAX-Konzern bei SpringWorks zu? | Die Aktie von Merck KGaA notiert weiterhin in der Nähe des 52-Wochen-Tiefs. Das bestätigte Übernahmeinteresse an SprinWorks Therapeutics hat den DAX-Wert jüngst unter Druck gesetzt, denn die Marktteilnehmer... ► Artikel lesen | |
| EVOTEC | 8,520 | -0,35 % | Evotec-Aktie kann Vortagsniveau nicht halten (8,49 €) | An der deutschen Börse liegt die Evotec-Aktie derzeit im Minus. Der jüngste Kurs betrug 8,49 Euro. Am Aktienmarkt liegt die Evotec-Aktie aktuell im Minus. Das Wertpapier verbilligte sich um 24 Cent.... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 36,810 | -1,58 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs | KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25 Kymera plans to initiate a KT-621 Phase 1b trial in atopic dermatitis (AD) patients in 2Q25 with data in 4Q25 and... ► Artikel lesen | |
| BIONTECH | 114,20 | +0,44 % | Vervielfachungspotenzial mit KI-Newcomer NetraMark! Palantir und BioNTech in einer Aktie! | "Gamechanger"! "Quantensprung"! "Revolution"! Für die Möglichkeiten von Künstlicher Intelligenz (KI) in der Medizin verwenden Experten zahlreiche Superlative. Fest steht, dass KI riesiges Potenzial... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 12,430 | +1,76 % | Day One Biopharmaceuticals, Inc.: Day One Reports Third Quarter 2024 Financial Results and Corporate Progress | Achieved $20.1 million in OJEMDATM (tovorafenib) net product revenue Ended the third quarter with $558.4 million in cash, cash equivalents and short-term investments Company to host conference call... ► Artikel lesen |
PSYENCE BIOMEDICAL LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,085 (-6,20 %) liegt der Kurs bei 1,285 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PSYENCE BIOMEDICAL LTD finden Sie auf Wallstreet Online.
